Ocular Myasthenia Gravis

Ocular myasthenia gravis (OMG) is an autoimmune disorder of the neuromuscular junction in which pathogenic antibodies (most often against the postsynaptic acetylcholine receptor, AChR) impair signal transmission at the motor end plate, producing fatigable weakness confined to the extraocular and eyelid muscles.¹ It is often called a "great masquerader" because it can mimic nearly any pattern of ptosis or ocular misalignment, including patterns resembling individual cranial nerve palsies or internuclear ophthalmoplegia, without following a single nerve's anatomic distribution. Categories include ocular MG (OMG, confined to extraocular/eyelid muscles), generalized MG (gMG, bulbar/limb/respiratory involvement), myasthenic crisis (respiratory failure requiring critical care), and antibody-based subtypes (AChR-positive, MuSK-positive, seronegative).

Systemic generalization from initially ocular-only disease occurs frequently: approximately half of OMG patients progress to generalized disease, most commonly within two years of onset.² Recognized predictors of generalization include AChR antibody seropositivity, abnormal repetitive nerve stimulation findings, older age at onset, presence of thymoma, and greater initial disease severity; early, frequent relapse of ocular symptoms has also been proposed as a potential additional predictor based on case-level observation.² In AChR-antibody-positive MG, circulating autoantibodies bind postsynaptic receptors, leading to receptor internalization, complement-mediated end-plate damage, and a reduced safety margin for neuromuscular transmission. Because this safety margin is already relatively narrow in extraocular muscles compared with skeletal muscle elsewhere, ocular muscles are disproportionately susceptible to early, isolated involvement.¹

Patients report variable, fluctuating ptosis and/or diplopia that characteristically worsens through the day, with sustained effort, or with fatigue, and improves with rest. The pattern of misalignment can shift over an exam or between visits — itself a diagnostic clue — and bilateral, asymmetric ptosis that varies in severity is particularly characteristic.

Key differentials: chronic progressive external ophthalmoplegia and other mitochondrial myopathies (symmetric, slowly progressive, no fatigability), thyroid eye disease (restrictive myopathy with proptosis/lid retraction), cranial nerve palsies (specific, reproducible anatomic pattern), internuclear ophthalmoplegia, and orbital/cavernous sinus vascular lesions — a cavernous sinus dural arteriovenous fistula has been reported to closely mimic OMG, including an initially positive edrophonium test, until atypical findings (persistent diplopia, new conjunctival injection) prompted neuroimaging revealing the true diagnosis.³

Bedside clues include fatigable ptosis (worsening with sustained upgaze), Cogan's lid twitch, a variable non-anatomic pattern of extraocular restriction, improvement with an ice pack applied to the closed lid, and a spared pupil (normal size and reactivity), distinguishing OMG from a pupil-involving CN III palsy. Diagnosis relies on this clinical picture plus confirmatory serology (AChR, then MuSK if negative) and electrophysiology (repetitive nerve stimulation, single-fiber EMG) when serology is unrevealing.¹ All confirmed MG patients should undergo chest imaging (CT or MRI) to screen for thymoma, regardless of whether disease is ocular or generalized.¹

Management is multimodal: acetylcholinesterase inhibitors (pyridostigmine) are typically first-line for symptomatic control, with immunomodulatory therapy (corticosteroids, steroid-sparing agents) added for inadequate response or higher-risk features. IVIg or plasma exchange is reserved for severe or refractory presentations, and thymectomy is considered in select cases, particularly with thymoma or younger AChR-positive patients with generalized disease.¹ Ongoing relapses of ocular symptoms despite treatment should prompt close monitoring for impending generalization and reconsideration of treatment strategy rather than being managed as isolated flares.²

• Fatigability, Cogan's lid twitch, and a positive ice-pack test are useful bedside clues; a spared pupil is one of the most useful features distinguishing OMG from a pupil-involving CN III palsy
• All confirmed MG patients should have chest imaging to screen for thymoma, not just those with additional systemic symptoms¹
• Roughly half of OMG patients generalize, usually within two years, guiding counseling and monitoring intensity²
• Even a positive edrophonium test does not guarantee OMG — atypical findings should prompt neuroimaging to exclude a vascular mimicker³
• Common pitfall: anchoring on an initial OMG diagnosis despite atypical findings rather than reconsidering the differential³
• Common pitfall: omitting chest imaging for thymoma screening in apparently isolated, mild ocular disease¹
• Common pitfall: failing to monitor respiratory and bulbar function given the possibility of progression to myasthenic crisis¹